Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Biodesix Inc

NASDAQ: BDSX · Industrial Applications and Services · 4 alerts · CIK 1439725

Share price
$9.00Close, Nov 16
Market cap
$99.8M
Shares outstanding
11.09MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Biodesix Inc filings on SEC EDGAR ↗

9:29 AM ET Form 4
Insider Buying

Biodesix 10% Owner Jack W. Schuler Buys $1M of Stock

Jack W. Schuler, 10% Owner, bought 100,000 shares of Biodesix Inc at $10.02 a share, worth $1M in total on Nov 10, 2026. Shares held after the trade: 655,810 (+18.0%).

Value
$1M
Shares
100,000
Price
$10.02
Role
10% Owner
Holding change
+18.0%
Trade date
Nov 10, 2026
4:11 PM ET 8-K
Leadership Change

Biodesix Leadership Change

Kieran O’Kane, the Chief Commercial Officer of Biodesix, Inc., departed the company effective November 2, 2026. He will be eligible for separation benefits under his existing Executive Severance and Change in Control Agreement as a result of his qualifying termination.

4:06 PM ET 10-Q
Financial Results

Biodesix Q3 2026 Results: Net Loss of $8.03M, Loss Narrows

Biodesix, Inc. reported total assets of $93.9 million as of September 30, 2026, an increase from $87.5 million at the end of 2025, primarily driven by a rise in cash and cash equivalents to $28.4 million. The company continues to operate as a non-accelerated filer and smaller reporting company, with 11,088,511 shares of common stock outstanding as of October 30, 2026.

Key figure
Net loss $8.03M
4:03 PM ET 8-K
Financial Results

Biodesix Financial Results

Biodesix reported Q3 2026 total revenue of $24.0 million, a 10% year-over-year increase driven by a 16% rise in Diagnostic Testing revenue. Despite the growth, the company revised its full-year 2026 revenue guidance downward to $101-$103 million, citing slower-than-expected sales representative contributions and seasonality.

Term
Q3 2026

“Biodesix delivered another quarter of year-over-year growth, with total revenue increasing 10%, Diagnostic Testing revenue increasing 16%, test volumes increasing 24%, and gross margin remaining strong at 81%. However, our growth was below our expectations, and we understand the principal drivers: fewer contributing sales representatives than planned limited new physician and account growth; greater-than-anticipated seasonality, primarily in primary care, reduced ordering frequency among otherwise stable base customers; and delays in external customer dependencies postponed the start of Development Services projects and the associated revenue recognition.”

Scott Hutton, Chief Executive Officer

“The factors that impacted the quarter were largely execution and timing related rather than a change in demand, clinical utility, or market opportunity. We have identified the drivers, taken corrective actions, and entered the fourth quarter with a larger sales organization positioned for improved execution.”

Scott Hutton, Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.